Caligan Partners LP
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Caligan Partners LP reported 12 stock positions worth $315.5 million. Its top holding was Liquidia (LQDA) at 25.7% of the portfolio, followed by Verona Pharma (VRNA, 13.1%) and Exelixis (EXEL, 12.6%). Compared with Q2 2024, it sold out of 1, added to 5 and reduced 6. The biggest buy was Evolus (EOLS, shares +1%) and the biggest sale an exit from Alimera Sciences (ALIM).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001727492
- Portfolio Value
- $315.5M (Q3 2024)
- SEC Filing
- 0001420506-24-002574 ↗ filed Nov 14, 2024
Holdings Value
Holdings 12 stocks · $315.5M
| LQDA Liquidia Corp. | 25.73% | 8,118,592 | $81.2M | Reduce -21.6% |
| VRNA Verona Pharma Ltd. | 13.10% | 1,436,878 | $41.3M | Reduce -22.1% |
| EXEL Exelixis Inc. | 12.55% | 1,525,730 | $39.6M | No change |
| EOLS Evolus Inc. | 11.26% | 2,193,488 | $35.5M | Add +1.2% |
| ANIK Anika Therapeutics Inc. | 11.24% | 1,435,130 | $35.4M | Reduce -0.1% |
| AGIO Agios Pharmaceuticals Inc. | 8.16% | 579,717 | $25.8M | Add +12.6% |
| BCRX Biocryst Pharmaceuticals Inc. | 6.22% | 2,583,585 | $19.6M | Reduce -43.8% |
| YMAB Y-Mabs Therapeutics Inc. | 4.98% | 1,195,253 | $15.7M | Add +105.3% |
| MLYS Mineralys Therapeutics Inc. | 3.77% | 981,155 | $11.9M | Add +31.6% |
| NBP Novabridge Biosciences filed as I MAB | 1.38% | 3,499,330 | $4.3M | Add +3.7% |
| ENTA Enanta Pharmaceuticals Inc. | 1.06% | 322,453 | $3.3M | Reduce -69.1% |
| OTLK Outlook Therapeutics Inc. | 0.54% | 318,699 | $1.7M | Reduce -36.3% |
Portfolio Sells Q2 2024 → Q3 2024
| ALIM Alimera Sciences Inc. | Sold out | 0.00% | −21.87 |
| LQDA Liquidia Corp. | Reduce -21.6% | 25.73% | −3.31 |
| ENTA Enanta Pharmaceuticals Inc. | Reduce -69.1% | 1.06% | −2.10 |
| BCRX Biocryst Pharmaceuticals Inc. | Reduce -43.8% | 6.22% | −0.42 |
| OTLK Outlook Therapeutics Inc. | Reduce -36.3% | 0.54% | −0.32 |
| ANIK Anika Therapeutics Inc. | Reduce -0.1% | 11.24% | +2.74 |
| VRNA Verona Pharma Ltd. | Reduce -22.1% | 13.10% | +6.87 |
Portfolio Buys Q2 2024 → Q3 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $2.1B | LQDA, RVMD, ABVX, PCVX, EXEL |
| Q1 2026 | 24 | $1.4B | LQDA, ABVX, RVMD, PCVX, XENE |
| Q4 2025 | 20 | $1.1B | LQDA, ABVX, RVMD, MLYS, PCVX |
| Q3 2025 | 16 | $720.7M | LQDA, ABVX, MLYS, EXEL, RVMD |
| Q2 2025 | 16 | $515.1M | VRNA, LQDA, EXEL, AGIO, MRUS |
| Q1 2025 | 16 | $479.2M | LQDA, VRNA, EXEL, MLYS, EOLS |
| Q4 2024 | 14 | $394.9M | LQDA, VRNA, EXEL, EOLS, ANIK |
| Q3 2024 | 12 | $315.5M | LQDA, VRNA, EXEL, EOLS, ANIK |
| Q2 2024 | 13 | $428.0M | LQDA, ALIM, ANIK, EXEL, BCRX |
| Q1 2024 | 12 | $378.3M | LQDA, ALIM, ANIK, EOLS, EXEL |